Clinical/Translational Cancer Immunotherapy
Section edited by James L. Gulley, MD, PhD and Douglas G. McNeel, MD, PhD
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Official journal of
- Editorial Board
- Sign up for article alerts and news from this journal